FDA Approves BIZENGRI — Merus US, Inc.

The FDA’s approval of Zenocutuzumab (Bizengri) on December 4 grants Merus US, Inc. commercial rights to a first-in-class therapy for NRG1 fusion-positive cancers, positioning the company to capture a valuable niche in the rare oncology market. This milestone is expected to drive robust revenue growth for Merus as it utilizes the drug’s intravenous administration to address a significant unmet medical need.